Harvard Bioscience, Inc. (HBIO) Analysts See $0.01 EPS

April 25, 2018 - By wolcottdaily

Harvard Bioscience, Inc. (NASDAQ:HBIO) LogoInvestors sentiment increased to 1.32 in Q4 2017. Its up 0.41, from 0.91 in 2017Q3. It improved, as 3 investors sold Harvard Bioscience, Inc. shares while 16 reduced holdings. 8 funds opened positions while 17 raised stakes. 22.13 million shares or 3.01% more from 21.49 million shares in 2017Q3 were reported.
Clarivest Asset Mgmt Ltd Limited Liability Company has 0.01% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 160,500 shares. Schwab Charles has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 19,300 shares. Sei Investments reported 0% stake. Bnp Paribas Arbitrage Sa invested in 0% or 2 shares. California Pub Employees Retirement System stated it has 139,202 shares. Geode Management Limited Liability has invested 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Panagora Asset Mngmt invested in 0% or 18,071 shares. Bard Assoc Inc stated it has 0.55% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Spark Investment Mngmt Limited Company invested in 0.01% or 60,700 shares. Wells Fargo And Co Mn holds 0% or 32,446 shares in its portfolio. 195,857 are owned by Gsa Capital Prtn Ltd Liability Partnership. Woodmont Investment Counsel Limited Liability Corp reported 176,091 shares. Earnest Prtnrs Ltd Liability Com accumulated 2,600 shares. Acadian Asset Mgmt Limited has invested 0.01% in Harvard Bioscience, Inc. (NASDAQ:HBIO). 3,537 were accumulated by Pnc Grp.

Since March 7, 2018, it had 0 insider buys, and 3 selling transactions for $1.00 million activity. The insider Duchemin Jeffrey sold 87,022 shares worth $393,963. UVEGES GEORGE sold $161,599 worth of stock or 35,054 shares.

Analysts expect Harvard Bioscience, Inc. (NASDAQ:HBIO) to report $0.01 EPS on April, 26.HBIO’s profit would be $356,032 giving it 147.50 P/E if the $0.01 EPS is correct. After having $0.04 EPS previously, Harvard Bioscience, Inc.’s analysts see -75.00 % EPS growth. The stock increased 1.72% or $0.1 during the last trading session, reaching $5.9. About 104,887 shares traded. Harvard Bioscience, Inc. (NASDAQ:HBIO) has risen 87.27% since April 25, 2017 and is uptrending. It has outperformed by 75.72% the S&P500.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Ratings Coverage

Among 2 analysts covering Harvard Bioscience (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience had 2 analyst reports since January 24, 2018 according to SRatingsIntel.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $210.06 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.